Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Demise

 With profound grief we inform you that Shri Soshil Kumar Jain (DIN: 00012812), the Founder, Chairman and the patriarch of Promoters family of Panacea Biotec Limited (the 'Company') has left for his heavenly abode on October 07, 2022. Further, as per Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the list of the promoters and promoters' group of the Company stands updated with exclusion of name of Shri Soshil Kumar Jain.
07-10-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

 Pursuant to Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with amended Rule 20 of Companies (Management and Administration) Rules, 2015, the detailed voting results along with the Scrutinizer's Report is enclosed herewith.
29-09-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Closure of Trading Window

 We would like to inform that the trading window of the Company shall remain closed for all the Designated Persons of the Company from October 01,2022 till completion of 48 hours from the announcement to the Stock Exchanges regarding Unaudited financial results of the Company for the quarter and half year ended September 30,2022. The date of meeting of the Board of Directors to approve the Unaudited financial results of the Company for the quarter and half year ended September 30, 2022, shall be informed in due course.
29-09-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Shareholder Meeting / Postal Ballot-Outcome of AGM

 Please find enclosed herewith proceedings of 38th Annual General Meeting ('AGM') of the Company held on Wednesday, September 28, 2022 at 11:30 A.M. through Video Conferencing ('VC'). The detailed voting results of all the businesses transacted at the AGM as set out in the AGM Notice along with the consolidated Scrutinizer's Report as required under Regulation 44 of the SEBI LODR Regulations shall be submitted in due course of time
29-09-2022

USFDA asks Panacea Biotec to take corrective measures at Himachal unit

 Panacea Biotec Ltd on Thursday said the US health regulator has asked for further corrective actions at the manufacturing unit of its wholly-owned arm at Baddi in Himachal Pradesh otherwise approval of any pending product applications from the facility may be withheld. The US Food and Drug Administration (USFDA) had inspected the Baddi unit of its subsidiary, Panacea Biotec Pharma Ltd (PBPL) from May 30 to June 8, 2022. Subsequently, the USFDA issued Form 483 with eight observations which are related to improvements in existing procedures and are addressable, Panacea Biotec said in a regulatory filing. According to the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The company said it has "now received a communication from the USFDA indicating the inspection classification .
08-09-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Update On The USFDA Inspection Of The Company'S Material Wholly-Owned Subsidiary, Panacea Biotec Pharma Limited'S Facility At Baddi, Himachal Pradesh, India

 This is with respect to our earlier communication dated 09.06.2022, we wish to inform you that Panacea Biotec Pharma Limited ('PBPL') has now received a communication from the USFDA indicating the inspection classification as 'Official Action Indicated' (OAI). The OAI classification implies, inter-alia, that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved. PBPL is working closely with USFDA to close these observations and the closure of Warning Letter issued by the USFDA earlier on 24.09.2020. We are committed to patient safety & quality and take quality & compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards. PBPL continues to manufacture and distribute existing products for the US market, thereby not likely to have any material adverse impact on current business from the facility.
08-09-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find attached herewith details of Shares dematerialized during August, 2022 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018
07-09-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In continuation to our letter dated September 06, 2022 and pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copies of the newspaper advertisements regarding Notice of AGM, Cut-off Date, Remote e- Voting information and Book Closure published on September 07, 2022 in Business Standard (All Editions) and Desh Sewak (Punjabi Edition).
07-09-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Corporate Action - Fixes Book Closure For Annual General Meeting To Be Held On September 28, 2022 At 11:30 A.M.

 We would like to inform you that for the purpose of Annual General Meeting to be held on September 28, 2022, the Register of Members and Share Transfer Books shall remain closed from 21.09.2022 to 28.09.2022 (both days inclusive). This is for your kind information and record please.
06-09-2022
Bigul

PANACEA BIOTEC LTD. - 531349 - Reg. 34 (1) Annual Report.

 We would like to inform you that 38th AGM of the Company is to be held on Wednesday, 28.09.2022 at 11:30 A.M. through VC / OAVM. A copy of Annual Report for FY 2021-22 sent to the shareholders through email is enclosed herewith for your reference.
06-09-2022
Next Page
Close

Let's Open Free Demat Account